Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Lyell Immunopharma (LYEL) Gains from Sales and Divestitures (2021)

Lyell Immunopharma (LYEL) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $4.0 million as the latest value for Q3 2021.